Cat. No.: HY-17381

Idarubicin hydrochloride

(Synonyms: 4-Demethoxydaunorubicin hydrochloride)

19 Cited Publications

Customer Review

Based on 19 publication(s) in Google Scholar

Idarubicin hydrochloride is an anthracycline antileukemic agent. It inhibits the topoisomerase II interfering with the replication of DNA and RNA transcription. Idarubicin hydrochloride inhibits the growth of bacteria and yeasts.

For research use only. We do not sell to patients.

Purity: 99.94%
CAS No.: 57852-57-0
Formula: C₂₆H₂₈ClNO₉
Molecular Weight:533.95

Storage:

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture and light)

Idarubicin hydrochloride Chemical Structure

CAS No.: 57852-57-0

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
Chemical Information
Publications (19)
Solvent & Solubility
- In Vitro
- In Vivo
Protocol
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]

Topoisomerase II

All Topoisomerase Isoforms :

All Antibiotic Isoforms :

All DNA/RNA Synthesis Isoforms :

In Vitro

The IC₅₀ of Idarubicin hydrochloride is 3.3±0.4 ng/mL on MCF-7 monolayers and 7.9±1.1 ng/mL in multicellular spheroids^[1]. Idarubicin hydrochloride has shown a greater cytotoxicity than daunorubicin or doxorubicin in various in vitro systems. This has been attributed to a better ability of idarubicin to induce the formation of topoisomerase II -mediated DNA breaks^[2]. Idarubicin hydrochloride is about 57.5-fold and 25-fold more active than doxorubicin and epirubicin, respectively^[3]. Idarubicin hydrochloride produces a concentration-dependent reduction in cell growth, with an IC₅₀ value of approximately 0.01 μM. Idarubicin hydrochloride produced a concentration-dependent inhibition of DNA synthesis^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 57852-57-0
Appearance Solid
Molecular Weight 533.95
Formula C₂₆H₂₈ClNO₉
Color Orange to red
SMILES

OC(C(C(C1=CC=CC=C21)=O)=C3C2=O)=C4[C@H](C[C@@](C(C)=O)(O)CC4=C3O)O[C@@](O[C@@H](C)[C@H]5O)([H])C[C@@H]5N.Cl
Synonyms

4-Demethoxydaunorubicin hydrochloride
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture and light)

Publications (19)

All Cell Proliferation/Viability AssayFlow CytometryWBIn Vivo Efficacy Study

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]

2025 Dec 15;10(1):406. PMID: 41392286
Nat Cell Biol

Trafficking circuit of CD8+ T cells between the intestine and bone marrow governs antitumour immunity. [Abstract]

2024 Aug;26(8):1346-1358. PMID: 39039181

Idarubicin hydrochloride purchased from MedChemExpress. Usage Cited in: Nat Cell Biol. 2024 Aug;26(8):1346-1358. [Abstract]

Number of total BM cells and GFP⁺ AF9 cells after treatment with 5 mg/kg DOX or 1 mg/kg Idarubicin hydrochloride for 5 days (n = 3 per group).
Nat Commun

Selective inhibition of cancer cell self-renewal through a Quisinostat-histone H1.0 axis. [Abstract]

2020 Apr 14;11(1):1792. PMID: 32286289
Nucleic Acids Res

ZYH005, a novel DNA intercalator, overcomes all-trans retinoic acid resistance in acute promyelocytic leukemia. [Abstract]

2018 Apr 20;46(7):3284-3297. PMID: 29554366

Idarubicin hydrochloride purchased from MedChemExpress. Usage Cited in: Nucleic Acids Res. 2018 Apr 20;46(7):3284-3297. [Abstract]

NB4 and NB4-LR2 cells were treated with ZYH005, Arsenic trioxide (ATO), 5-fluorouracil (5-Fu), Cisplatin (DDP), Doxorubicin (DOX) and Idarubicin hydrochloride (IDA) at 0.05 μM for 24 h, and then cell apoptosis was determined.
Cell Rep Med

CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]

2025 Apr 15;6(4):102053. PMID: 40187357
Sci Adv

Tissue-specific inflammation induces cell state plasticity with oncogenic addiction in mucosal melanoma. [Abstract]

2026 Apr 3;12(14):eady4536. PMID: 41920996
Cancer Lett

Synthetic lethality of combined AT-101 with idarubicin in acute myeloid leukemia via blockade of DNA repair and activation of intrinsic apoptotic pathway. [Abstract]

2019 Oct 1:461:31-43. PMID: 31301319
Anal Chem

Force-Dependent Intercalative Bulky DNA Adduct Formation Detected by Single-Molecule Stretching. [Abstract]

2022 Oct 4;94(39):13623-13630. PMID: 36129494
Cancer Cell Int

GANT61 surmounts drug resistance of ADR by upregulating lysosome activities and reducing BCL2 expression in HL-60/ADR cells. [Abstract]

2024 Dec 26;24(1):430. PMID: 39726048
Biochem Pharmacol

Deubiquitinase USP5 promotes acute myeloid leukemia through C2CD5 stabilization and PI3K/AKT/mTOR/HIF-1α-driven glycolysis. [Abstract]

2026 Feb:244:117591. PMID: 41344512
J Mol Med (Berl)

Combination of PARP inhibitor and temozolomide to suppress chordoma progression. [Abstract]

2019 Aug;97(8):1183-1193. PMID: 31201471
iScience

RHOF activation of AKT/β-catenin signaling pathway drives acute myeloid leukemia progression and chemotherapy resistance. [Abstract]

2024 Jun 8;27(7):110221. PMID: 39021805

Idarubicin hydrochloride purchased from MedChemExpress. Usage Cited in: iScience. 2024 Jun 8;27(7):110221. [Abstract]

THP-1 and MOLM-13 cells (control for knockdown or shRHOF) were treated with 1.2 μM Ara-C and 0.03 μg/mL Idarubicin hydrochloride for 48 h to measure apoptosis via flow cytometry (n = 3). Student's t tests were used for comparing two variables.

Idarubicin hydrochloride purchased from MedChemExpress. Usage Cited in: iScience. 2024 Jun 8;27(7):110221. [Abstract]

THP-1 and MOLM-13 cells (control for overexpression or RHOF) were treated with 1.2 μM Ara-C and 0.03 μg/mL Idarubicin hydrochloride for 48 h to measure apoptosis via flow cytometry (n = 3). Student's t tests were used for comparing two variables.
J Virol

Cellular DNA Topoisomerases Are Required for the Synthesis of Hepatitis B Virus Covalently Closed Circular DNA. [Abstract]

2019 May 15;93(11):e02230-18. PMID: 30867306

Idarubicin hydrochloride purchased from MedChemExpress. Usage Cited in: J Virol. 2019 May 15;93(11):e02230-18. [Abstract]

Idarubicin hydrochloride reduced HBV cccDNA levels in a dose-dependent manner, but had no effect on core DNA and DP-rcDNA levels.
Viruses

Broad-Spectrum Host-Based Antivirals Targeting the Interferon and Lipogenesis Pathways as Potential Treatment Options for the Pandemic Coronavirus Disease 2019 (COVID-19). [Abstract]

2020 Jun 10;12(6):628. PMID: 32532085
Mol Carcinog

circSLC25A13 acts as a ceRNA to regulate AML progression via miR-616-3p/ADCY2 axis. [Abstract]

2023 Oct;62(10):1546-1562. PMID: 37493101
Exp Cell Res

Network-based analysis with primary cells reveals drug response landscape of acute myeloid leukemia. [Abstract]

2020 Aug 1;393(1):112054. PMID: 32376287
Hematology

XPO1 inhibitor selinexor suppresses homologous recombination by inhibiting E2F7 nuclear export in acute myeloid leukemia. [Abstract]

2026 Dec 31;31(1):2664314. PMID: 42026967
bioRxiv

2023 Jan 13.
University of Paris

2022 Sep 19.

Solvent & Solubility

In Vitro:

DMSO : 83.33 mg/mL (156.06 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.8728 mL

9.3642 mL

18.7283 mL

5 mM

0.3746 mL

1.8728 mL

3.7457 mL

10 mM

0.1873 mL

0.9364 mL

1.8728 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture and light). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (3.90 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (3.90 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocol

Cell Assay^[1]

Stock solutions of idarubicin hydrochloride is dissolved in distilled water (1 mg/mL). MCF-7 monolayer are exposed to idarubicin or its metabolite idarubicinol at 0.01, 0.1, 1, 10, 100, and 1000 ng/mL for 24 hours. Multicellular spheroids are exposed to the same range of idarubicin　and idarubicinol concentration as monolayers (0.01-1000 ng/mL) for 24 h and, in separate experiments, at the drug concentration of 100 ng/mL for 6, 12, 24 and 48 h. The inhibition of cell proliferation is determined by counting the viable cells with an hemocytometer. Results are expressed as percentage of cell survival vs. control cultures^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (281 KB)
SDS (644 KB)
- English - EN (644 KB)
- Français - FR (644 KB)
- Deutsch - DE (644 KB)
- Norwegian - NO (644 KB)
- Español - ES (644 KB)
- Swedish - SV (644 KB)
- Italian - IT (644 KB)
- Korean - KR (644 KB)
- Portuguese - PT (644 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Orlandi P, et al. Idarubicin and idarubicinol effects on breast cancer multicellular spheroids. J Chemother. 2005 Dec;17(6):663-7. [Content Brief]

[2]. Robert J. Clinical pharmacokinetics of idarubicin. Clin Pharmacokinet. 1993 Apr;24(4):275-88. [Content Brief]

[3]. Siegsmund MJ, et al. Enhanced in vitro cytotoxicity of idarubicin compared to epirubicin and doxorubicin in rat prostate carcinoma cells. Eur Urol. 1997;31(3):365-70. [Content Brief]

[4]. Gewirtz DA, et al. Induction of DNA damage, inhibition of DNA synthesis and suppression of c-myc expression by the anthracycline analog, idarubicin (4-demethoxy-daunorubicin) in the MCF-7 breast tumor cell line. Cancer Chemother Pharmacol. 1998;41(5):361- [Content Brief]

[5]. Kinnunen U, et al. Idarubicin inhibits the growth of bacteria and yeasts in an automated blood culture system. Eur J Clin Microbiol Infect Dis. 2009 Mar;28(3):301-3. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.8728 mL	9.3642 mL	18.7283 mL	46.8209 mL
	5 mM	0.3746 mL	1.8728 mL	3.7457 mL	9.3642 mL
	10 mM	0.1873 mL	0.9364 mL	1.8728 mL	4.6821 mL
	15 mM	0.1249 mL	0.6243 mL	1.2486 mL	3.1214 mL
	20 mM	0.0936 mL	0.4682 mL	0.9364 mL	2.3410 mL
	25 mM	0.0749 mL	0.3746 mL	0.7491 mL	1.8728 mL
	30 mM	0.0624 mL	0.3121 mL	0.6243 mL	1.5607 mL
	40 mM	0.0468 mL	0.2341 mL	0.4682 mL	1.1705 mL
	50 mM	0.0375 mL	0.1873 mL	0.3746 mL	0.9364 mL
	60 mM	0.0312 mL	0.1561 mL	0.3121 mL	0.7803 mL
	80 mM	0.0234 mL	0.1171 mL	0.2341 mL	0.5853 mL
	100 mM	0.0187 mL	0.0936 mL	0.1873 mL	0.4682 mL

Keywords

Idarubicin hydrochloride

19 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Idarubicin hydrochloride

Bioactive Compound Library Max

Bioactive Compound Library

Anti-Infection Compound Library

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Antifungal Compound Library

Antibacterial Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

Glutamine Metabolism Compound Library

FDA Approved & Pharmacopeial Drug Library

Antibiotics Library

Anti-Lung Cancer Compound Library

Drug-Induced Liver Injury (DILI) Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Transcription Factor-Targeted Library

Rare Diseases Drug Library

Pediatric Drug Library

Chemotherapy Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Off-patent Drug Library

Mitochondrial Protection Compound Library

Mitochondrial Toxicity Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Cell Proliferation Compound Library

Lactic Acid Metabolic Compound Library

High-Throughput Bioactive Compound Library

Anti-Cancer Approved Drug Library

Mass Spectrometry Human Metabolite Library

Cardiotoxic Compound Library

Publications Citing Use of MedChemExpress (MCE) Idarubicin hydrochloride

All Topoisomerase Isoforms

All Antibiotic Isoforms

All DNA/RNA Synthesis Isoforms

Biological Activity

Chemical Information

Publications (19)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Idarubicin hydrochloride Related Classifications

HY-17381 Related Classifications